Evidence map›Paper›PMID 41314617›Full record

Trial reportAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026

Pharmacokinetics, lineage identity, and trafficking of ex vivo expanded polyclonal regulatory T cells in a prospective randomized clinical trial of kidney transplant recipients with allograft inflammation.

Sindhu Chandran, Joey C Leung, Alexander Vu, Karim Lee, Mark Fitch, Jonathan H Esensten, Brian R Shy, Amy L Putnam, Angela Lares, Luis A Acevedo and 14 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02711826 (Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02711826 phase1 / phase2completednot on this map

Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation (CTOT-21)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2016 to 2023Enrolled32ConditionsKidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney DonorArmsPolyclonal Regulatory T Cells, Everolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sindhu ChandranDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Joey C LeungDepartment of Surgery, University of California San Francisco, San Francisco, California, USA.
Alexander VuDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Karim LeeDepartment of Surgery, University of California San Francisco, San Francisco, California, USA.
Mark FitchDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, California, USA.
Jonathan H EsenstenDepartment of Lab Medicine, University of California San Francisco, San Francisco, California, USA.
Brian R ShyDepartment of Lab Medicine, University of California San Francisco, San Francisco, California, USA; Gladstone-UCSF Institute of Genome Immunology, San Francisco, California, USA.
Amy L PutnamDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Angela LaresDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Luis A AcevedoDepartment of Lab Medicine, University of California San Francisco, San Francisco, California, USA.
Vinh NguyenDepartment of Surgery, University of California San Francisco, San Francisco, California, USA.
Weihong LiuDiabetes Center, University of California San Francisco, San Francisco, California, USA.
Brian ArmstrongBiostatistics, Rho Inc., Durham, North Carolina, USA.
Zoltan G LaszikDepartment of Pathology, University of California San Francisco, San Francisco, California, USA.
Roslyn B MannonDepartment of Medicine, University of Alabama, Birmingham, Alabama, USA.
John J FriedewaldComprehensive Transplant Center, Northwestern University, Chicago, Illinois, USA.
Abhijit NaikDepartment of Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Scott DavisDepartment of Medicine, University of Colorado, Aurora, Colorado, USA.
Minnie SarwalDepartment of Surgery, University of California San Francisco, San Francisco, California, USA.
Marc HellersteinDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, California, USA.
Megan MorsheimerNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Julia GoldsteinNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Qizhi TangDepartment of Surgery, University of California San Francisco, San Francisco, California, USA; Diabetes Center, University of California San Francisco, San Francisco, California, USA; Gladstone-UCSF Institute of Genome Immunology, San Francisco, California, USA. Electronic address: Qizhi.Tang@ucsf.edu.
Flavio G VincentiDepartment of Medicine, University of California San Francisco, San Francisco, California, USA; Department of Surgery, University of California San Francisco, San Francisco, California, USA. Electronic address: flavio.vincenti@ucsf.edu.

Funding

Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1M
Novel Therapies to Modulate the Inflammatory Alloresponse in Renal GraftsU01AI113362 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VINCENTI, FLAVIO · 2014 to 2023
$15.2M
NIAID NIH HHS U01 AI113362NIAID NIH HHS UM2 AI117870
6 · The paper itself

Abstract

Regulatory T cells (Tregs) can reverse inflammation in animal models. We conducted a randomized controlled clinical trial of Treg therapy in kidney transplant recipients with subclinical graft inflammation (NCT02711826). The primary endpoint was the change in graft inflammation on a follow-up biopsy 6 months after Treg infusion. The trial accrued 8 control group participants and 7 polyclonal Treg group participants; the latter received 400 × 10

Indexed as

Graft RejectionInflammationKidney Failure, ChronicKidney TransplantationT-Lymphocytes, RegulatoryAdultAllograftsFemaleFollow-Up StudiesGlomerular Filtration RateGraft SurvivalHumansKidney Function TestsMaleMiddle AgedPrognosisborderline changecellular therapyimmune modulationimmune regulationkidney transplantpolyclonal regulatory T cellsprotocol biopsyregulatory T cellssubclinical rejectionT cell biologyT cell lineage identityT cell trafficking

Identifiers

PMID41314617
PMCPMC12971219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.